Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Ideaya Biosciences Inc

Company price
27.4 USD -2.96 ( 9.75%)
Last update at 2026-11-17T21:00:00Z
VOLUME
2042523
Market Cap
3633.79M

Momentum Score

…

IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings. The company also offers IDE849, a DLL3 antibody drug conjugate inhibitor for the treatment of SCLC and neuroendocrine carcinomas; IDE034, a B7H3/PTK7 topo-I-payload bispecific BsADC; IDE161, a poly ADP-ribose glycohydrolase inhibitor; IDE705 (GSK101), a Poly Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other mutations associated with HRD; IDE397, a MAT2A inhibitor for MTAP-deleted tumors; IDE892, a PRMT5 inhibitor; IDE574 selectively inhibits KAT6/7 and is in Phase 1 dose escalation trial for patients with breast, lung, prostate, and colorectal cancers; IDE275 oral small molecule inhibitor of the helicase domain of the Werner protein (WRN) and is in a Phase 1 clinical trial. In addition, the company offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Gilead Sciences, Inc., Novartis, Biocytogen, Cancer Research UK, the University of Manchester, Jiangsu Hengrui Pharmaceuticals Co., Ltd., and Les Laboratoires Servie. It also has a clinical collaboration agreement with AstraZeneca plc to evaluate IDE849, an antibody-drug conjugate; and clinical collaboration with Roche to evaluate IDE892, IDEAYA's potential best-in-class Phase 1 MTA-cooperative PRMT5 inhibitor, in combination with RG6505, Roche's Phase 1 pan-R

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
26.68
Low
31.85
High
52 Week Price Range
24.95
Low
42.68
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Ideaya Biosciences is a clinical‑stage precision oncology company developing small‑molecule therapies that exploit synthetic lethality and DNA damage response (DDR) vulnerabilities. Long‑term growth may be supported by clinical trial readouts, biomarker‑directed patient selection and collaborations with larger biopharma partners that could aid development and commercialization, which may attract investors seeking exposure to DDR‑targeted oncology.
Main risks are high clinical and regulatory uncertainty, ongoing funding and dilution needs, and intense competition from larger oncology companies.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
30.36
Dividend Yield
-
Revenue TTM
234.13M
Revenue Per Share
2.62
Gross Profit TTM
-139.88M
Debt / Equity
0.03
ROE
-16.22%
Net Debt
-84.91M
ROCE
-15.17%
Diluted EPS TTM
-1.90

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -113.70M -274.48M -112.96M -58.66M -49.76M
Net income -113.70M -274.48M -112.96M -54.81M -47.53M
Selling general administrative 63.32M 39.30M 28.31M 23.90M 20.05M
Gross profit -95.99M 3.17M 19.38M 50.93M 27.94M
Reconciled depreciation 4.59M 3.83M 4.01M 2.10M 1.73M
Ebit -159.31M -274.48M -112.96M -64.60M -51.99M
Ebitda -154.72M -270.64M -108.95M -62.50M -50.27M
Depreciation and amortization 4.59M 3.83M 4.01M 2.10M 1.73M
Non operating income net other - - - 3.85M 0.51M
Operating income -159.31M -326.98M -134.43M -62.50M -50.27M
Other operating expenses 378.02M 333.98M 157.81M 113.43M 78.21M
Interest expense - - 21.47M 3.85M 0.51M
Interest income 45.62M 52.50M 21.47M 3.85M 0.51M
Net interest income 45.62M 52.50M 21.47M 3.85M 0.51M
Income tax expense - - 3.84M -3.85M -2.23M
Total revenue 218.71M 7.00M 23.39M 50.93M 27.94M
Total operating expenses 63.32M 330.14M 153.81M 113.43M 78.21M
Cost of revenue 314.70M 3.83M 4.01M - -
Total other income expense net 45.62M 52.50M 21.47M 3.85M 0.51M
Net income from continuing ops -113.70M -274.48M -112.96M -58.66M -49.76M
Net income applicable to common shares - - - -58.66M -49.76M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 1109.32M 1124.09M 649.32M 387.97M 381.35M
Other current assets 21.37M 13.39M -632.61M 5.41M 3.12M
Total liab 86.39M 64.94M 28.23M 387.97M 381.35M
Total stockholder equity 1022.93M 1059.15M 621.09M 349.45M 301.51M
Other current liab 40.89M 30.35M 18.76M 17.00M 12.32M
Common stock 0.01M 0.01M 0.01M 0.01M 0.00M
Capital stock 0.01M 0.01M 0.01M 0.01M 0.00M
Retained earnings -736.54M -622.84M -348.36M -235.40M -176.75M
Other liab - - - 5.18M 31.19M
Other assets - - - 0.20M 0.40M
Cash 112.83M 84.38M 157.02M 68.63M 92.05M
Total current liabilities 58.81M 46.07M 27.10M 31.72M 45.16M
Current deferred revenue - - - 8.57M 29.04M
Net debt -84.91M -65.21M -154.15M -65.15M -86.86M
Short term debt 0.34M 0.30M 1.75M 1.87M 1.70M
Short long term debt total 27.91M 19.17M 2.87M 3.48M 5.18M
Other stockholder equity 1757.20M 1681.17M 968.88M 587.72M 478.97M
Property plant equipment - - - 6.51M 4.76M
Total current assets 666.73M 689.71M 532.63M 370.45M 251.00M
Long term investments 410.30M 405.83M 107.49M 8.32M 121.29M
Net tangible assets - - - 349.45M 301.51M
Short term investments 526.56M 591.94M 368.10M 296.20M 154.72M
Net receivables 5.97M 0.00M 0.02M 0.21M 1.10M
Inventory - - 532.61M -8.32M -121.29M
Accounts payable 17.58M 15.42M 6.60M 4.28M 2.10M
Accumulated other comprehensive income 2.27M 0.81M 0.56M -2.87M -0.71M
Common stock total equity - - - 0.01M 0.00M
Retained earnings total equity - - - -235.40M -176.75M
Non currrent assets other 1.01M 0.81M 0.78M 0.20M 0.40M
Non current assets total 442.60M 434.38M 116.68M 17.52M 130.35M
Capital lease obligations 27.91M 19.17M 2.87M 3.48M 5.18M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 72.34M -502.56M -56.79M -29.96M -67.02M
Change to liabilities - - - 6.44M 5.38M
Total cashflows from investing activities 69.98M -502.56M -158.46M -33.40M -69.67M
Total cash from financing activities 29.78M 677.55M 362.72M 97.17M 145.45M
Change to operating activities - - - 2.17M 3.79M
Net income -113.70M -274.48M -112.96M -58.66M -49.76M
Change in cash 28.45M -72.59M 89.04M -23.41M 20.01M
Begin period cash flow 84.38M 157.78M 68.74M 92.15M 72.14M
End period cash flow 112.83M 85.18M 157.78M 68.74M 92.15M
Total cash from operating activities -71.10M -247.58M -115.22M -87.17M -55.78M
Issuance of capital stock 24.86M 663.63M 181.83M 94.96M 143.25M
Depreciation 4.59M 3.83M 4.01M 2.10M 1.73M
Other cashflows from investing activities 69.98M - - - -
Change to inventory - - -2.28M - 3.79M
Change to account receivables 0.00M 0.01M 0.19M 0.89M 0.77M
Sale purchase of stock - - - 88.31M 88.19M
Other cashflows from financing activities 29.78M 23.32M 52.95M 2.20M 2.20M
Change to netincome - - - 11.63M 8.24M
Capital expenditures 2.37M 3.86M 2.37M 3.44M 2.64M
Change receivables - - - 0.89M 0.77M
Cash flows other operating - - - -48.88M -23.96M
Cash and cash equivalents changes - - - -23.41M 20.01M
Change in working capital 1.87M 11.55M -13.21M -41.55M -17.81M
Stock based compensation 46.12M 34.75M 18.49M 11.63M 8.24M
Other non cash items -9.98M -23.23M -11.55M -0.69M 1.83M
Free cash flow -73.47M -251.44M -117.59M -90.62M -58.42M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
IDYA
Ideaya Biosciences Inc
-2.96
9.75%
27.40 - 4.65 15.52 3.06 12.26 -7.80
NVO
Novo Nordisk A/S
-0.99
2.39%
40.60 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc
-3.90
0.73%
533.89 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc
5.36
0.56%
957.76 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE
-
-%
965.00 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Ideaya Biosciences Inc

IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings. The company also offers IDE849, a DLL3 antibody drug conjugate inhibitor for the treatment of SCLC and neuroendocrine carcinomas; IDE034, a B7H3/PTK7 topo-I-payload bispecific BsADC; IDE161, a poly ADP-ribose glycohydrolase inhibitor; IDE705 (GSK101), a Poly Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other mutations associated with HRD; IDE397, a MAT2A inhibitor for MTAP-deleted tumors; IDE892, a PRMT5 inhibitor; IDE574 selectively inhibits KAT6/7 and is in Phase 1 dose escalation trial for patients with breast, lung, prostate, and colorectal cancers; IDE275 oral small molecule inhibitor of the helicase domain of the Werner protein (WRN) and is in a Phase 1 clinical trial. In addition, the company offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Gilead Sciences, Inc., Novartis, Biocytogen, Cancer Research UK, the University of Manchester, Jiangsu Hengrui Pharmaceuticals Co., Ltd., and Les Laboratoires Servie. It also has a clinical collaboration agreement with AstraZeneca plc to evaluate IDE849, an antibody-drug conjugate; and clinical collaboration with Roche to evaluate IDE892, IDEAYA's potential best-in-class Phase 1 MTA-cooperative PRMT5 inhibitor, in combination with RG6505, Roche's Phase 1 pan-R

5000 Shoreline Court, South San Francisco, CA, United States, 94080

650 443 6209

145

Name Title Year Born
Mr. Yujiro S. Hata Co-Founder, CEO, Pres & Director 1974
Mr. Paul A. Stone Sr. VP, CFO & Principal Accounting Officer 1964
Dr. Michael A. White Ph.D. Sr. VP & Chief Scientific Officer 1965
Dr. Jeffrey Hager Ph.D. Co -Founder 1964
Mr. Andres Ruiz Briseno CPA VP and Head of Bus. Operations & IR 1986
Mr. Jason S. Throne J.D., Esq. Sr. VP, Gen. Counsel & Company Sec. 1972
Dr. Paul A. Barsanti Ph.D. Sr. VP & Head of Drug Discovery NA
Dr. Matthew Maurer M.D. VP and Head of Medical Affairs & Clinical Oncology NA
Mr. Mick O'Quigley Sr. VP of Devel. Operations NA
Dr. Darrin M. Beaupre M.D., Ph.D. Sr. VP & Chief Medical Officer NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…